Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma (Q34563164)

3 August 2017

title

Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma (English)

1 reference

3 August 2017

0 references

0 references

0 references

1 reference

Eva Kimby

3

1 reference

ORCID Public Data File 2021

author name string

Jenny Flygare

1

1 reference

3 August 2017

Kristin Gustafsson

2

1 reference

3 August 2017

Birger Christensson

4

1 reference

3 August 2017

Birgitta Sander

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

3 August 2017

1 reference

3 August 2017

volume

579

1 reference

3 August 2017

issue

30

1 reference

3 August 2017

page(s)

6885-6889

1 reference

Mantle cell lymphoma: a biological and therapeutic paradigm

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Cannabinoid receptor as a novel target for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Cannabinoid-based drugs as anti-inflammatory therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Binding of anandamide to bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.11.020

10.1016/J.FEBSLET.2005.11.020

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference